When it comes to third world medicine we almost invariably hear from the WHO about the successes of massive vaccination programs. If you look into the recent agenda for the World Health Assembly  you will find pandemic influenza vaccines at the top of the technical matters, and in the status section, the eradication of Poliomyelitis is at the top of that section. What is glaringly absent is a discussion of the pervasive double standards in research ethics, health-care safety and professional rigor that exist in the developing world. The WHO and its medical partners won’t talk about it publicly because when you look at the numbers, it is directly implicated in the suffering and ultimate death of millions of people in the developing world. That is what we’ll cover in this piece.
It is well known that needle re-use can be a major cause of virus transmission. In 2000, a WHO press release states:
Unsafe Injection practices have serious large-scale consequences…”unsafe injection practices throughout the world result in millions of infections which may lead to serious disease and death. Each year over-use of injections and re-use of dirty syringes and needles combine to cause an estimated 8 – 18 million hepatitis B virus infections, 2.3-4.7 million hepatitis C virus infections and 80,000 – 160,000 infections with HIV/AIDS worldwide. 
That same press release uses an epidemic of Hepatitis C that occurred from Schistosomiasis treatment in Egypt. Notably absent is any discussion of the massive immunization campaigns waged throughout the third world coincident with the massive epidemics of HIV and other infectious diseases. However, someone there must be aware of the potential problem because the press release states the following at the end:
In addition, to ensure the safety of immunization injections, WHO, the United Nations Children’s Fund (UNICEF), the United Nations Population Fund (UNFPA), and the International Federation of the Red Cross and Red Crescent Societies (IFRC) have recently called for the exclusive use of auto-disable (AD) syringes for immunization by the end of 2003.
We know quite reliably that the WHO knew years prior to this press release (2003) that medical practices in the developing world were problematic. As Gisselquist outlines in his 2009 article  the WHO was quietly giving UN employees the following advice in 1991.
take special precautions to avoid HIV transmission via blood . . . If you are not carrying your own needles and syringes, avoid having injections unless they are absolutely necessary . . . Avoid tattooing and ear-piercing. Avoid any procedures that pierce the skin, such as acupuncture and dental work, unless they are genuinely necessary. Before submitting to any treatment that may give an entry point to HIV, ask whether the instruments to be used have been properly sterilized.
Mumps outbreaks are occurring in highly vaccinated populations and this has led to differences in opinion amongst scientists around the efficacy of the vaccine, with various mechanisms of failure being put forward. It has been suggested that the number of vaccinated young adults (18-24 yrs) who contracted mumps in the US in 2006 form a small percentage of the overall vaccinated population. The fact that 84% were vaccinated with two doses is reduced to a minor detail when numbers are crunched in the “right” way. However, this is not the view of all scientists. There is concern as to why highly vaccinated populations are having mumps outbreaks. By choosing to avoid the issue, essentially ignoring the reason why young adults who have been vaccinated twice with the MMR are coming down with mumps, the evidence on the real efficacy of mass vaccination against a benign childhood disease is not discussed. Read more
VIENNA, Aug 28 (Reuters) – Austrian biotech firm Intercell <ICEL.VI> said on Thursday its partner Merck & Co <MRK.N> has started a Phase II clinical trial to evaluate a vaccine candidate against Staphylococcus aureus infections.
Merck is responsible for clinical development, manufacturing and marketing of the vaccine. Intercell is eligible to receive milestone payments and royalties on future net sales
This is the second trial start following a separate Phase II trial launch in December 2007. Read more
Remember the Great Influenza Vaccine Shortage a few years back?
Panic swept the nation after the FDA rejected many European flu shots because of possible contamination during manufacturing. What was left was rationed according to age and risk factors, and the public could be seen every night on the news waiting in long lines to get the remaining doses.
Now, setting aside for the moment the ongoing questions regarding the usefulness of flu shots in any age group, especially the elderly, one might come to wonder what has changed in recent years to bring about this new terror regarding influenza.
The answer, as outlandish and implausible as it might sound, is that this fear has been manufactured and marketed by the people in public health. Read more
Insidevaccines is three months old today. In three months our team of writers, editors and proofreaders have put together 23 articles. In the days just before our opening on February 1st we also compiled 22 pages of useful information on a wide variety of vaccine related topics. We have linked to published scientific papers, to the Centers for Disease Control and to manufacturer’s product inserts.
We would like to thank all of the people who have spread links to insidevaccines across the web, with special thanks to Sandy Gottstein of Vaccination News and Ginger Taylor of Adventures in Autism for adding our link to their sites.
Disclaimer: Insidevaccines, although it is three months old, has not yet received any of the CDC recommended vaccines. Enter at your peril!